A lysosomal storage disorder where lipid trafficking defects affect the liver, spleen, lungs, and brain — and where nutrition goals shift dramatically between subtypes
Niemann-Pick Disease (NPD) is an umbrella term for several rare inherited lysosomal lipid storage disorders. Despite sharing a name, the subtypes differ significantly in their biochemical defects, clinical features, and nutritional implications. Understanding which type is relevant to you or your family member is essential before any dietary approach is considered.
The three clinically relevant subtypes are:
NPB patients who survive into adulthood — with appropriate medical support — face a distinctive metabolic profile that makes weight management challenging:
The liver and spleen enlarge significantly due to sphingomyelin-laden macrophages (foam cells) accumulating in these organs. Massive splenomegaly causes early satiety (the enlarged spleen physically compresses the stomach), abdominal discomfort, and reduced appetite. Paradoxically, some patients lose weight due to this, while others gain weight as mobility declines.
Abdominal fullness means large meals are not tolerated. Multiple small meals (5-6 per day) are often better tolerated than three large ones. Contact sports and heavy lifting are contraindicated due to the risk of splenic rupture — this significantly limits exercise options.
NPB causes a distinctive lipid pattern: very low HDL cholesterol, elevated LDL cholesterol, and elevated triglycerides. This dramatically increases cardiovascular disease risk — NPB patients have accelerated atherosclerosis. Standard lipid-lowering dietary principles apply: reduced saturated fat, minimal trans-fat, increased soluble fibre (oats, legumes, barley), and omega-3 fatty acids (oily fish, flaxseed).
Statins are often used but must be approached with caution given hepatic involvement — discuss the risk-benefit with your hepatologist.
Sphingomyelin accumulation in alveolar macrophages (pulmonary alveolar proteinosis pattern) reduces gas exchange capacity. Many NPB adults have reduced exercise tolerance due to pulmonary restriction. Aerobic exercise should be started at low intensity and progressed very gradually based on oxygen saturation monitoring.
Low platelets (from splenic sequestration) mean that high-impact exercise with injury risk should be avoided. Bruising and bleeding risk must factor into exercise selection.
The diet for an adult NPB patient pursuing weight management must simultaneously address cardiovascular risk (dyslipidaemia), hepatic health (large fatty liver), splenic protection (no impact sports, no alcohol), and practical eating around early satiety from organomegaly:
In NPC, the weight and nutrition challenge is very different from NPB. The primary concern is neurological deterioration — ataxia, dystonia, and dementia progressively impair swallowing (dysphagia), increasing aspiration pneumonia risk. Weight loss in NPC is typically the problem, not excess weight.
Miglustat (Zavesca) — a substrate reduction therapy — slows neurological progression in NPC and is the only approved disease-modifying therapy. It causes significant gastrointestinal side effects (diarrhoea, bloating, flatulence) and a requirement to avoid simple sugars in the diet. A low-disaccharide, low-simple-sugar diet is recommended during miglustat therapy to manage these GI effects.
Progressive dysphagia in NPC requires a speech-language therapist (SLT) assessment to determine safe food textures and liquid consistencies. The IDDSI (International Dysphagia Diet Standardisation Initiative) framework is used to prescribe appropriate texture levels. As the disease progresses, gastrostomy tube feeding (PEG tube) is often required to maintain calorie and fluid intake safely and reduce aspiration pneumonia risk.
| NPC Stage | Typical Nutritional Issue | Approach |
|---|---|---|
| Early (childhood/adolescent) | Normal or near-normal intake; miglustat GI side effects | Low-simple-sugar diet; small frequent meals |
| Intermediate (progressive ataxia) | Dysphagia emerging; aspiration risk | SLT assessment; texture modification; thickened liquids |
| Advanced (severe neurological) | Oral feeding unsafe; weight loss, dehydration | PEG gastrostomy; high-calorie tube feeds; prevent aspiration |
For NPB adults with some preserved mobility:
For NPC patients, exercise has been shown to slow neurological decline in early-to-intermediate stages. Neurological physiotherapy focusing on balance, coordination, and gait is the priority. The goal is not calorie burning but preserving neurological function.
Olipudase alfa (Xenpozyme) — recombinant acid sphingomyelinase — received regulatory approval for non-neurological NPD (NPB) and represents the first disease-modifying therapy for this condition. Clinical trials showed significant reductions in hepatic and splenic volume and improvements in pulmonary function. Access in South Africa is through compassionate use or specialist application to the National Department of Health. Discuss with your metabolic physician.
Niemann-Pick Disease is managed at the same specialist metabolic centres as other lysosomal storage disorders: Red Cross War Memorial Children's Hospital (Cape Town), Wits Donald Gordon Medical Centre and Steve Biko Academic Hospital (Johannesburg), and Inkosi Albert Luthuli Central Hospital (Durban). The South African Society for Inborn Errors of Metabolism (SASIEM) can assist with referrals.
Need more condition-specific content? Browse our full library of South African weight management guides for rare and complex conditions.